1. Home
  2. Live Updates
  3. Akero Therapeutics (AKRO) Reports Encouraging 36-Week Analys

Akero Therapeutics (AKRO) Reports Encouraging 36-Week Analys

Akero Therapeutics (AKRO) Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study

Akero Therapeutics (AKRO) Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Americans , Andrew Cheng , Pa Fibroscan , Stephen Harrison , Akero Therapeutics Inc , Pinnacle Clinical Research , Nasdaq , Akero Therapeutics , Liver Biopsy Analysis Set , Non Invasive Markers , Change From Baseline , Full Analysis , Serum Markers , Conference Call ,